Give science a mission, and offer products with excellence
R&D and innovation have always been the foundation of Gan & Lee Pharmaceuticals, and have always been our constant ambition. The Company has never stopped advancing and exploring product development and technological innovation, in order to continuously improve the treatment of diabetes and to further enhance the quality of life of patients. We have consistently adhered to the culture of “Science & Excellence” to challenge the limits of human cognition with continuous innovation and try to find better solutions.
Having developed the first Chinese domestic insulin analog, Gan & Lee has a complete R&D pipeline for insulin and related products. Currently, we havefive recombinant insulin analogs commercialized and one human insulin injectionapproved in China. Our products cover the three sub-markets of insulin, namely long-acting, fast-acting and mixed insulin, and we are dedicated to providing more and better insulin therapeutic options to patients globally.
We are also actively engaged in the development of medicinal products in related fields. The clinical application of GLP-1RA (GZR18), an innovative therapeutic biological product, has been accepted by the China National Medical Products Administration (NMPA), for the treatment of type II diabetes, obesity, and overweight.
At Gan & Lee, we are aiming to develop innovative therapies to improve and prolong the lives of those with cancer. Our original innovative drug GLR2007 has entered a phase I clinical trial in the U.S. in July 2020 and has started the clinical trial in China simultaneously, to establish the safety, tolerability, and optimal dosing strategy of GLR2007 in patients with advanced solid tumors.
So far, GLR2007 has been granted Orphan Drug Designation by the Food and Drug Administration (FDA) in the US and European Medical Administration (EMA), for the treatment of malignant glioma and glioma respectively, while also being granted Fast Track Designation by the U.S. FDA, for the treatment of Glioblastoma (GBM).
Gan & Lee develops medical devices to support the treatment of diabetes. GanleeFine, an injection pen needle for insulin received clearance from the U.S. Food and Drug Administration (FDA).
We hope to develop a new generation of cloud data management of blood glucose monitoring and insulin injection products through the combination of “Internet Plus”, a model of online medical service so that we can bring more convenient, better therapeutic options to diabetic patients globally.
Copyright 2021 Gan & Lee Pharmaceuticals Co Ltd . All Rights Reserved.
You are now leaving the Gan & Lee website.
The site you are about to visit is maintained by a third party who is responsible for its content.